KRAS-targeted cancer vaccine shows promise Final results from the AMPLIFY-201 phase 1 trial highlight durable T cell responses and prolonged survival in patients with colorectal and pancreatic cancer.

https://www.drugdiscoverynews.com/kras-targeted-vaccine-shows-promise-16685?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-9Bq7rVfKUDz8idJlzURxTgq0bzgNW3_5jtnvjeGXokjmm9S4ry8X9MmD-o7l5XUawcYQLSBs_PzUy6JQ4KsEzy2pOQlA&_hsmi=382247589&utm_content=382247589&utm_source=hs_email